Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Sumio Ohtsuki
Faculty of Life Sciences, Kumamoto University
Read more
10,261 registered articles
(updated on August 07, 2020)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
2019 Journal Impact Factor (JIF)
Scopus Pubmed
Featured article
Volume 43 (2020) Issue 8 Pages 1147-1153
Development of Multi-functional Nanoparticles for Clinical Application to Gene and Nucleic Acid Medicines Read more
Editor’s picks

The clinical application of gene/nucleic acid medicines is highly dependent on the development of effective and reliable drug delivery systems. Dr. Sasaki successfully developed several ternary complexes as novel gene delivery carriers, which were constructed by gene/nucleic acid medicine, the cationic polymer, and the anionic polymer. This ternary complex consists of biodegradable materials found in foods and medical products that are already in clinical use and can deliver gene/nucleic acid medicines to specific organs (liver, spleen, lung, and cancer cells etc.) without toxicity. The ternary complexes are expected to apply to clinical practice.

Volume 43 (2020) Issue 8 Pages 1172-1178
Isosteviol Sodium Attenuates High Fat/High Cholesterol-Induced Kidney Dysfunction by Inhibiting Inflammation, Oxidative Stress and Apoptosis Read more
Editor’s picks

The sodium salt of isosteviol (STVNa) is a beyerane diterpene synthesized through acid hydrolysis of stevioside. STVNa improves multiple types of tissue injuries. However, it is not known how Isosteviol sodium affects high-fat and high cholesterol diet (HFD)-induced kidney. The current study suggested that STVNa inhibited HFD-induced kidney injury evident by reducing the increased levels of serum CRE. Specifically, STVNa attenuated HFD-induced kidney injury by inhibiting inflammation, oxidative stress, and apoptosis. These findings indicate that STVNa may have a therapeutic potential for metabolic syndrome associated kidney dysfunction by inhibiting inflammation, oxidative stress and apoptosis.

Volume 43 (2020) Issue 8 Pages 1188-1195
Enhanced Immunostimulatory Activity of CpG Oligodeoxynucleotide by the Combination of Mannose Modification and Incorporation into Nanostructured DNA Read more
Editor’s picks

Increasing the immunostimulatory activity of unmethylated cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) is an important issue for its clinical application as immunoadjuvant. In this study, the authors combined two approaches, i.e., nanostructured DNA formation and mannose modification, for efficient delivery of CpG ODN to mannose receptor-positive immune cells. Mannosylated CpG ODN (Man-CpG ODN) loaded onto polypod-like structured nucleic acid (polypodna) induced a greater tumor necrosis factor-α release than Man-CpG ODN or CpG ODN/polypodna from the cells. Thus, this study provides a new and promising approach to increasing the therapeutic potency of CpG ODN.

Volume 43 (2020) Issue 8 Pages 1248-1252
Trends of Antifungal Use Based on Sales Data in Japan from 2006 to 2015 Read more
Editor’s picks

The detailed epidemiology of invasive mycoses and superficial mycoses has not been clarified in Japan. This is the first study to clarify the trends of antifungal use in Japan. The authors found that total antifungal use decreased over time. Notably, the trend of antifungal use for invasive mycoses was significantly increased by 19.9% whereas the trend of antifungal use for superficial mycoses significantly decreased by 49.8%. In Japan, the increase in the number of immunocompromised patients might be associated with an increase in the frequency of antifungal use for invasive mycoses.

Volume 43 (2020) Issue 8 Pages 1259-1266
Development and Testing of an Individual Kernel Detection System for Genetically Modified Soybean Events in Non-identity-preserved Soybean Samples Read more
Editor’s picks

Today, majority of soybeans in Japan comes from foreign countries, where genetically modified (GM) soybeans are cultivated. The details of GM soybean actually consumed for food in Japan have been unknown. The article by Soga et al. reported a quantitative GM soybean kernel detection system and that the most of imported soybean in the non-identity-preserved soybean samples examined were herbicide-tolerant and insect-resistant GM soybean events that were authorized in Japan. These data would provide useful information on risk analysis concerning regulations on GM soybean for food use.

View all featured articles
View all articles in Current issue
Most viewed articles Jul.2020
Share this page
Select past volume & issue
Announcements from publisher
  • Biol. Pharm. Bull. Vol. 43 No. 4 Current Topics: Recent  Advances  in  Research  on  Particulate  Formulations  such  as  Lipoproteins,  Liposomes,  Extracellular  Vesicles,  and  iPS-Derived  Cells
  • Biol. Pharm. Bull. Vol. 43 No. 3
    Current Topics: Drug Discovery: Recent Progress and the Future

  • Biol. Pharm. Bull. Vol. 43 No. 2
    Current Topics: Challenges in the Control of Environmental Pathogenic Microbes
  • Biol. Pharm. Bull. Vol. 43 No. 1
    Current Topics: Recent Advances in Research on the Mechanisms and Regulation of Allergic Diseases